Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Acceptable performance of blood biomarker tests of amyloid pathology — recommendations from the Global CEO Initiative on Alzheimer’s Disease
Suzanne E. Schindler, Douglas Galasko, Ana C. Pereira, et al.
Nature Reviews Neurology (2024) Vol. 20, Iss. 7, pp. 426-439
Open Access | Times Cited: 58

Showing 1-25 of 58 citing articles:

Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
Clifford R. Jack, J. Scott Andrews, Thomas G. Beach, et al.
Alzheimer s & Dementia (2024) Vol. 20, Iss. 8, pp. 5143-5169
Open Access | Times Cited: 367
Alzheimer Disease as a Clinical-Biological Construct—An International Working Group Recommendation
Bruno Dubois, Nicolas Villain, Lon S. Schneider, et al.
JAMA Neurology (2024)
Closed Access | Times Cited: 30
Head‐to‐head comparison of leading blood tests for Alzheimer's disease pathology
Suzanne E. Schindler, Kellen K. Petersen, Benjamin Saef, et al.
Alzheimer s & Dementia (2024) Vol. 20, Iss. 11, pp. 8074-8096
Open Access | Times Cited: 15
Blood phosphorylated Tau181 reliably differentiates amyloid‐positive from amyloid‐negative subjects in the Alzheimer's disease continuum: A systematic review and meta‐analysis
Annibale Antonioni, Emanuela Maria Raho, Lamberto Manzoli, et al.
Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring (2025) Vol. 17, Iss. 1
Open Access | Times Cited: 4
Use of lecanemab and donanemab in the Canadian healthcare system: Evidence, challenges, and areas for future research
Eric E. Smith, Natalie A. Phillips, Howard Feldman, et al.
The Journal of Prevention of Alzheimer s Disease (2025), pp. 100068-100068
Open Access | Times Cited: 1
Transcriptome analysis of early‐ and late‐onset Alzheimer's disease in Korean cohorts
Sang‐Won Han, Jiyun Hwang, Tamina Park, et al.
Alzheimer s & Dementia (2025) Vol. 21, Iss. 2
Open Access | Times Cited: 1
Optimizing cutpoints for clinical interpretation of brain amyloid status using plasma p‐tau217 immunoassays
Daniel Figdore, Michael Griswold, Joshua A. Bornhorst, et al.
Alzheimer s & Dementia (2024) Vol. 20, Iss. 9, pp. 6506-6516
Open Access | Times Cited: 12
Recommendations for clinical implementation of blood‐based biomarkers for Alzheimer's disease
Michelle M. Mielke, Matthew Anderson, J. Wesson Ashford, et al.
Alzheimer s & Dementia (2024) Vol. 20, Iss. 11, pp. 8216-8224
Open Access | Times Cited: 9
A clinical perspective on the revised criteria for diagnosis and staging of Alzheimer’s disease
Oskar Hansson, Clifford R. Jack
Nature Aging (2024) Vol. 4, Iss. 8, pp. 1029-1031
Closed Access | Times Cited: 8
Blood-Based Biomarkers for Alzheimer Disease—Ready for Primary Care?
Lawren VandeVrede, Gil D. Rabinovici
JAMA Neurology (2024) Vol. 81, Iss. 10, pp. 1030-1030
Closed Access | Times Cited: 6
A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker tests
Noëlle Warmenhoven, Gemma Salvadó, Shorena Janelidze, et al.
Brain (2024)
Open Access | Times Cited: 5
Plasma p‐tau217 and neurofilament/p‐tau217 ratio in differentiating Alzheimer's disease from syndromes associated with frontotemporal lobar degeneration
Alberto Benussi, Hanna Huber, Kübra Tan, et al.
Alzheimer s & Dementia (2025)
Open Access
Which plasma pTau217 assay should I use in clinical practice? Pandora’s box demystified
Sofia Toniolo
Brain (2025) Vol. 148, Iss. 2, pp. 354-356
Closed Access
Clinical Utility of an Alzheimer’s Disease Blood Test Among Cognitively Impaired Patients: Results from the Quality Improvement PrecivityAD2 (QUIP II) Clinician Survey Study
Mark Monane, Demetrius M. Maraganore, Robert G. Carlile, et al.
Diagnostics (2025) Vol. 15, Iss. 2, pp. 167-167
Open Access
Cutting through the noise: A narrative review of Alzheimer's disease plasma biomarkers for routine clinical use
Michael Schöll, Agathe Vrillon, Takeshi Ikeuchi, et al.
The Journal of Prevention of Alzheimer s Disease (2025), pp. 100056-100056
Open Access
Clinical utility of plasma p‐tau217 in identifying abnormal brain amyloid burden in an Asian cohort with high prevalence of concomitant cerebrovascular disease
Joyce R. Chong, Saima Hilal, Boon Yeow Tan, et al.
Alzheimer s & Dementia (2025)
Open Access
Plasma N‐terminal tau fragment is an amyloid‐dependent biomarker in Alzheimer's disease
Guoyu Lan, Laihong Zhang, Anqi Li, et al.
Alzheimer s & Dementia (2025)
Open Access
Analytical Validation and Performance of a Blood-Based P-tau217 Diagnostic Test for Alzheimer Disease
Adam Abel, Antonio Chambers, Jeff A. Fill, et al.
The Journal of Applied Laboratory Medicine (2025)
Open Access
Evaluation of plasma p-tau217 for detecting amyloid pathology in a diverse and heterogeneous community-based cohort
Marc D. Rudolph, Courtney L. Sutphen, Thomas C. Register, et al.
medRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Core blood biomarkers of Alzheimer's disease: A single-center real-world performance study
Federico Emanuele Pozzi, Elisa Conti, Giulia Remoli, et al.
The Journal of Prevention of Alzheimer s Disease (2025) Vol. 12, Iss. 2, pp. 100027-100027
Open Access
Diagnostic performance of plasma biomarkers for Alzheimer's disease using a fully automated platform: A real-world clinical study
Fausto Roveta, Elisa Rubino, Andrea Marcinnò, et al.
Journal of Alzheimer s Disease (2025)
Open Access
Uncovering dark mass in population proteomics: Pan-analysis of single amino acid polymorphism relevant to cognition and aging
Xiaojing Gao, Yuanyuan Yin, Yiqian Chen, et al.
Cell Genomics (2025), pp. 100763-100763
Open Access
Clinical performance of the fully automated Lumipulse plasma p‐tau217 assay in mild cognitive impairment and mild dementia
Adam H. Dyer, Jean Dunne, Helena Dolphin, et al.
Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring (2025) Vol. 17, Iss. 1
Open Access
A head‐to‐head comparison of plasma biomarkers to detect Alzheimer's disease in a memory clinic
Federica Anastasi, Aída Fernández-Lebrero, Nicholas J. Ashton, et al.
Alzheimer s & Dementia (2025) Vol. 21, Iss. 2
Open Access
Blood phosphorylated Tau217 distinguishes amyloid-positive from amyloid-negative subjects in the Alzheimer's disease continuum. A systematic review and meta-analysis
Annibale Antonioni, Emanuela Maria Raho, Francesco Di Lorenzo, et al.
Journal of Neurology (2025) Vol. 272, Iss. 3
Open Access
Page 1 - Next Page

Scroll to top